Richard A. Miller, MD
Known title: President and CEOCIK: 0001031847
Richard A. Miller, MD's purchase track record
How the stock did after each of Richard A. Miller, MD's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
9
of 10 since August 20, 2021
Stock higher 6 months later
22%
3 months: 40%
Median 6-month return
-4.1%
3 months: -4.1%
Beat the S&P 500
33%
median -2.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2026 | CRVS | $83K | +22.1% | pending | — |
| 5/6/2024 | CRVS | $1000K | +47.6% | +372.3% | +10.3% |
| 12/13/2022 | CRVS | $45K | -11.5% | +329.3% | +8.7% |
| 9/28/2022 | CRVS | $19K | +3.6% | -4.9% | +8.3% |
| 9/20/2022 | CRVS | $16K | -1.3% | -13.3% | +3.8% |
| 6/24/2022 | CRVS | $10K | -14.9% | -4.1% | -1.7% |
| 6/2/2022 | CRVS | $6K | -6.9% | -1.5% | -2.4% |
| 3/31/2022 | CRVS | $25K | -39.6% | -52.3% | -19.6% |
| 3/15/2022 | CRVS | $45K | -35.6% | -36.2% | -7.7% |
| 8/20/2021 | CRVS | $19K | +83.3% | -3.1% | -2.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRVS | ▲ Buy | Open Market | 5,000 | $60K | 5/18/2026 | View on chart |
| CRVS | ▲ Buy | Open Market | 1,932 | $23K | 5/18/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 559,073 | $2.0M | 5/7/2025 | View on chart |
| CRVS | ▼ Sell | Gift | 302,016 | $0 | 5/10/2024 | View on chart |
| CRVS | ▲ Buy | Open Market | 577,634 | $1000K | 5/6/2024 | View on chart |
| CRVS | ▲ Buy | Open Market | 10,000 | $8K | 12/14/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 50,000 | $37K | 12/13/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 25,000 | $19K | 9/28/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 12,300 | $10K | 9/20/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 2,700 | $2K | 9/20/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 5,000 | $4K | 9/20/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 5,000 | $5K | 6/27/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 5,000 | $5K | 6/24/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 890 | $899 | 6/6/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 4,830 | $5K | 6/2/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 170 | $165 | 6/2/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 15,000 | $25K | 3/31/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 5,000 | $8K | 3/17/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 25,000 | $37K | 3/15/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 10,000 | $19K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript Released
Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.
Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.